Partin Nomogram

Updated Partin Nomogram to Help Predict Pathologic Stage of Prostate Cancer

The Partin nomogram uses preoperative Gleason grade, serum prostate specific antigen and clinical stage to predict pathological outcome after radical prostatectomy.

Below you will find links to the 2007 Partin Nomogram Quick Reference Guide – Based on cases from 2000 to 2005.

Click here to view Partin Nomogram Clinical Stage T1c

Click here to view Partin Nomogram Clinical Stage T2a

Click here to view Partin Nomogram Clinical Stage T2b

Corrected for the effect of stage migration

  • Previous nomogram determined staging algorithms based on cohorts different from contemporary prostate cancer patients1
  • According to the American Cancer Society, 90% of newly diagnosed prostate cancer patients present with localized or regional disease2
  • Probability of organ confined disease has increased from 2001 nomogram to 2007 version, even among T2b/T2c patients1

“Clinicians can use these nomograms based on the large cohort of men with CaP treated at our institution [Johns Hopkins, Department of Urology], to counsel individual patients and help them make important decisions.”1
aAdapted from Marakov et al. 2007
bResults from an analysis of 5730 men treated with prostatectomy (without additional therapy) between 2000 and 2005 at the Johns Hopkins Hospital. The objective was to update the 2001 “Partin tables” with a contemporary patient cohort to reflect trends in presentation and pathologic stage for men with clinically localized prostate cancer1
References:
1. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69(6):1095-1101
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. GA Cancer J Clin. 2005;55(1):10-30

©2010 Abott Laboratories Abbott Park, IL 60064